QIBA PET Amyloid Biomarker Committee
08 April 2016 at 9:00 AM CT (GMT-6)
Call Summary

In attendance:
Eric Perlman, MD (Co-Chair)  Martin Lodge, PhD  Charles Smith, MSCS  Joe Koudelik
Anne Smith, PhD (Co-Chair)  Dawn Matthews, MS, MBA  John Sunderland, PhD  Julie Lisiecki
William Bridge, MS  Nancy Obuchowski, PhD  Jean-Luc Vanderheyden, PhD
Susan De Santi, PhD  Sara Sheikbahaei, PhD  Richard Wahl, MD, FACR
Paul Kinahan, PhD

QIBA Round-6 Project Proposals
- Proposals are being drafted by project champions
  o Phantom and DRO (Drs. Sunderland and Kinahan)
  o Tracer uptake time differential effect (Drs. Boellaard and Vanderheyden)
- Feasibility test – collaboration with ADNI (may be considered for future funding)
  o Modeled after FDG Tumor Profile work
- Software/Reader variability project – modeled after Dr. Wahl’s project for the FDG Tumor Profile
  o Compare different analysis packages and readers (unless software is fully automated)
  o Dr. Obuchowski is willing to offer statistical support for this project
  o ADNI may be a good partner or provide a good dataset to use
  o Advantageous to incorporate different tracers: PET amyloid radiopharmaceutical vendors may contribute data
- Scanner reconstruction/image analysis impact on SUVR project
  o Ms. Matthews and Dr. Smith may review major points with the Round-5 project
  o Group guidance would be helpful – topics under investigation include:
    ▪ Difference between recon algorithms (FBP, OSEM, PSF and their TOF versions)
    ▪ Number of iterations (OSEM: 2, 3, 4, 5, 6)
    ▪ Gaussian filter size (OSEM: 2, 5, 7 mm)
  o Ms. Matthews plans to submit a project proposal on this topic and is open to suggestions
  o Dr. Smith to contact Dr. DeSanti about obtaining Siemens mCT scanner data from Piramal (done)
- Project proposals (including budget detail) are due to QIBA by April 15th: qiba@rsna.org

Profile
- The Profile was last updated on April 7, 2016.
- As there are over 100 different comments, Dr. Perlman has enlisted the aid of a colleague to act as interim Profile editor to help the group and clean up this latest version for readability.
- Some open issues remain that will require with the input of physics experts
- Dr. Obuchowski will also need to re-review the statistics sections to check for accuracy
- No additional confounders were found
- SUVr will be used instead of absolute SUV
- Some additional details are needed for the Patient Prep section 3.1.2

Action item: RSNA staff to re-distribute NIBIB application forms / details to all NM BC leaders

April Nuclear Medicine WebEx Calls:

<table>
<thead>
<tr>
<th>Biomarker Committees</th>
<th>SPECT Task Forces: (Tuesdays, 2 pm CT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apr 15: No call after QIBA Mtg</td>
<td>Apr 19: Phantoms / DRO – Drs. Dickson &amp; Zimmerman</td>
</tr>
<tr>
<td>Apr 22: SPECT BC</td>
<td>Apr 26: Clinical / Literature Review – Dr. Seibyl</td>
</tr>
<tr>
<td>Apr 29: TBD</td>
<td></td>
</tr>
</tbody>
</table>

1